SCHEMBL7704877

SCHEMBL7704877

COc1cccc(CC(NC(=O)OC(C)(C)C)c2ccc3c(c2)N=C(N)C(C)O3)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 8/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
CTSK P43235 1/20 0.37
HPGD P15428 4/20 0.37
HTT P42858 4/20 0.37
NPSR1 Q6W5P4 4/20 0.37
HSD17B10 Q99714 4/20 0.37
LMNA P02545 3/20 0.37
PKM P14618 3/20 0.37
TSHR P16473 2/20 0.37
TP53 P04637 2/20 0.37
MAPT P10636 1/20 0.37
AGTR1 P30556 1/20 0.37
RAB9A P51151 1/20 0.37
JAK2 O60674 2/20 0.36
ALOX15 P16050 1/20 0.36
XBP1 P17861 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7704948 0.92 SMN1; SMN2 (0.40) CACNA1BSMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL7704912 0.91 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1KMT2AMEN1CTSK
SCHEMBL7704904 0.90 CTSL (0.45) SMN1; SMN2ALDH1A1KMT2AMEN1CTSK
SCHEMBL7711250 0.90 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1KMT2AMEN1CTSK
SCHEMBL7711187 0.89 SIRT2 (0.38) SMN1; SMN2ALDH1A1KMT2AMEN1HPGD
SCHEMBL7711362 0.89 PTPRB (0.40) SMN1; SMN2ALDH1A1KMT2AMEN1HPGD
SCHEMBL7711369 0.87 ALDH1A1 (0.37) SMN1; SMN2ALDH1A1KMT2AMEN1CTSK
SCHEMBL7708193 0.86 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1KMT2AMEN1CTSK
SCHEMBL7711460 0.86 ALDH1A1 (0.34) SMN1; SMN2ALDH1A1KMT2AMEN1HPGD
SCHEMBL7708356 0.85 CTSS (0.41) SMN1; SMN2ALDH1A1KMT2AMEN1CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed